Enterprise Value
3.634B
Cash
402.9M
Avg Qtr Burn
-13.91M
Short % of Float
8.23%
Insider Ownership
0.23%
Institutional Own.
97.71%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NUPLAZID® (pimavanserin) (serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors) Details PDP (Parkinsons disease psychosis) | Approved Quarterly sales | |
DAYBUE™ (Trofinetide ) Details Rett syndrome | Approved Quarterly sales | |
sNDA FDA meeting | ||
Phase 3 Data readout | ||
ACP-204 Details Alzheimer's disease | Phase 1 Update | |
ACP-044 Details Pain, Post operative acute pain | Failed Discontinued |